BORRELIA BURGDORFERI GARINII ANTIBODY (CLONE BG14)
Borrelia burgdorferi garinii antibody (clone Bg14), is a mouse monoclonal recognising Borrelia burgdorferi garinii. The antibody is suitable for use in ELISA, Western blotting and immunofluorescence applications.
PRODUCT DETAILS – BORRELIA BURGDORFERI GARINII ANTIBODY (CLONE BG14)
- Mouse anti-B. burgdorferi garinii IgG 1 monoclonal antibody (clone Bg14).
- Greater than 95% purity by SDS-PAGE and buffered in PBS, ph7.4.
- Suitable for use in ELISA, Western blotting and immunofluorescence applications.
BACKGROUND
Borrelia burgdorferi garinii is a spirochete belonging to the Borrelia burgdorferi sensu lato species complex of spirochetes. It is a member of the genus Borrelia of the family Spirochaetaceae. In nature, spirochetes are maintained in a transmission cycle between hard ticks of the Ixodes species and a reservoir of small to medium sized vertebrate, and in some cases birds. In humans, infection occurs through the bite of a tick infected with the spirochete. Infection with B.burgdorferi in humans can cause the condition known as Lymes disease or Lyme borreliosis. Five Borrelia species have been reported to infect humans including B. burgdorferi sensu stricto in North America and Europe, B. garinii, B. bavariensis, B. afzelii in Europe and Asia, and B. spielmanii in Europe. B. afzelii and B. garinii account for most cases of Lymes disease in Europe (Wang, G), which are transmitted by the hard tick Ixodes Ricinus and maintained in small vertebrates and birds.
In humans, the most common clinical manifestation of infection is a large red rash, referred to as erythema migrans, which can vary in size and appearance. Additional symptoms include fever, chills, headache, fatigue, joint pains and swollen lymph nodes. However, in some severe cases, the infection may spread to joints, nervous system or heart and clinical symptoms including neck stiffness, arthritis, facial palsy, heart palpitations, nerve pain, numbness and memory loss may develop (CDC). Erythema migrans generally resolves without treatment. However, patients with Lyme disease are often treated with antibiotics to prevent dissemination and potential development of more severe clinical symptoms. Currently, no licensed vaccine to prevent Borrelia burgdorferi infection is available.
REFERENCES
- Wang G, Liveris D, Mukherjee P, Jungnick S, Margos G, Schwartz I. 2014. Molecular Typing of Borrelia burgdorferi. Curr Protoc Microbiol. Aug 1;34:12C.5.1-31
- Centers for Disease Control and Prevention: Lyme Disease.
